Gilead Sciences (GILD) has announced that it will invest $300 million to acquire a 49.9 percent equity interest in Tizona Therapeutics, Inc.
According to health authorities in South Korea, one third of seriously ill Covid-19 patients showed an improvement in their condition after being treated …
Australia’s Therapeutic Goods Administration (TGA) has granted provisional approval to Gilead Sciences’ (GILD) remdesivir (“Veklury”) as the first treatment option for COVID-19. It …
Gilead Sciences (GILD) has announced encouraging additional data on remdesivir, the company’s investigational antiviral for the treatment of COVID-19. The data includes a …
Gilead Sciences Inc. (GILD) on Monday priced its experimental coronavirus drug candidate remdesivir at $2,340 per patient for a 5-day treatment in the …
Gilead Sciences Inc. (GILD) announced on Tuesday that it will buy a 49.
Gilead Sciences Inc. (GILD) said it expects to produce more than 2 million treatment courses of its experimental coronavirus drug candidate remdesivir by …
India’s drug regulator granted Cipla Ltd. and Hetero Labs the approval to produce and sell a generic version of Gilead Sciences Inc.
Dr Reddy’s Laboratories Ltd. (RDY) announced that it has entered into a non-exclusive licensing agreement to manufacture and sell Gilead Sciences Inc.
Gilead Sciences (GILD) has now filed for conditional marketing authorization (CMA) of its antiviral medicine remdesivir for the treatment of COVID-19 with the European Medicines …
